MedTrace Logo

A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma

NCT07250594 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2025-11-26

No results posted yet for this study

Summary

1. Eosinophilic asthma, a type 2 immune disorder, often involves the excessive production of type 2 cytokines.
2. Excessive Type 2 cytokines lead to chronic inflammation, airway hyperresponsiveness, and airflow obstruction.
3. AD17002 is an intranasal self-applicable immunomodulator.
4. AD17002 is safe and tolerable in all studied clinical trials.
5. AD17002 elevates local type-1 interferon levels and promotes epithelial healing.
6. Type-1 interferons have been demonstrated to restore immune balance and reduce eosinophilic infiltration.

AD17002, an innate immune modulator, is likely to be effective as an add-on therapy to control poorly managed moderate to severe eosinophilic asthma.

Conditions

Interventions

BIOLOGICAL

AD17002

The IP, AD17002, will be provided in a container, each containing an appropriate number of IP pre-filled, self-administered syringes. Each container will be labeled as required per local requirements

OTHER

Formulation buffer

The placebo will be provided in a container, each containing an appropriate volume of formulation buffer, pre-filled syringes for self-administration. Each container will be labeled as required per local requirements

Sponsors & Collaborators

  • Advagene Biopharma Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-31
Primary Completion
2026-10-31
Completion
2026-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07250594 on ClinicalTrials.gov